Therapeutic use of agonists of the nuclear receptor PPARγ in Alzheimer's disease

Current Alzheimer Research

Volumn 4, Issue 2, 2007, Pages 159-164

  Landreth, Gary ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Diabetes; Insulin sensitizers; Nuclear receptors; Peroxisome proliferator activated receptor gamma

Indexed keywords

AMYLOID BETA PROTEIN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLIAZONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; HUMAN; INFLAMMATION; LIPID METABOLISM; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS; HUMANS; NEUROPROTECTIVE AGENTS; PPAR GAMMA;

EID: 34147102288     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507780362092     Document Type: Review

References (50)

1. Stampfer MJ. Cardiovascular disease and Alzheimer's disease: common links. J Intern Med 260: 211-23. (2006).
2. Berger J and Moller DE. The mechanisms of action of PPARs. Annu Rev Med, 53: 409-35. (2002).
3. Lehrke M and Lazar M. The many faces of PPARgamma. Cell 123: 993-9. (2005).
4. Glass CK and Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14: 121-41. (2000).
5. McKenna NJ and O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108: 465-74. (2002).
6. Daynes RA and Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2: 748-59. (2002).
7. McKay LI and Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20: 435-59. (1999).
8. Craft S. Insulin resistance syndrome and Alzheimer's disease: ageand obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging, 26 Suppl 1: 65-9. (2005).
9. Watson G and Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharm 490: 97-113. (2004).
10. Reger MA, Watson GS, Frey 2nd WH, Baker LD, Cholerton B, Keeling ML, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging, 27: 451-8. (2006).
11. Watson GS and Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17: 27-45. (2003).
12. Luchsinger JA, Tang MX, Stern Y, Shea S and Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154: 635-41. (2001).
13. Peila R, Rodriguez BL and Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51: 1256-62. (2002).
14. Landreth GE and Heneka MT. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22: 937-44. (2001).
15. Kielian T and Drew PD. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res 71: 315-25. (2003).
16. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421. (2000).
17. Ricote M, Li AC, Willson TM, Kelly CJ and Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82. (1998).
18. Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wullner U and Klockgether T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol 100: 156-68. (1999).
19. Heneka MT, Klockgether T and Feinstein DL. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci, 20: 6862-7. (2000).
20. Combs CK, Johnson DE, Karlo JC, Cannady SB and Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20: 558-67. (2000).
21. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M and Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittel-Forschung 47: 29-35. (1997).
22. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23: 7504-9. (2003).
23. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128: 1442-53. (2005).
24. Garcia-Bueno B, Madrigal J, Lizasoain I, Moro M, Lorenzo P and Leza J. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psych 57: 885-94. (2005).
25. Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'Amico M, D'Angelo B, et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130: 325-37. (2005).
26. Sundararajan S, Jiang Q, Heneka M and Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 49: 136-44. (2006).
27. Klotz L, Sastre M, Kreutz A, Gavrilyuk V, Klockgether T, Feinstein DL, et al. Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. J Neurochem 86: 907-16. (2003).
28. Fuenzalida K, Aguilera M, Piderit D, Ramos P, Contador D, Quinones V, et al. Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells J Biol Chem 280: 9604-9. (2005).
29. Uryu S, Harada J, Hisamoto M and Oda T. Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res 924: 229-36. (2002).
30. Aoun P, Simpkins J and Agarwal N. Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest. Ophth Vis Sci 44: 2999-3004. (2003).
31. Inestrosa N, Godoy J, Quintanilla R, Koenig C and Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res 304: 91-104. (2005).
32. Zhao X, Ou Z, Grotta JC, Waxham N and Aronowski J. Peroxisome- proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res (2006).
33. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23: 9796-804. (2003).
34. Sastre M, Klockgether T and Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci, (2006).
35. d'Abramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, Dalla Piccola B, et al. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 391: 693-8. (2005).
36. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D and De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24: 10908-17. (2004).
37. Costello DA, O'Leary DM and Herron CE. Agonists of peroxisome proliferator-activated receptor-gamma attenuate the Abetamediated impairment of LTP in the hippocampus in vitro. Neuropharmacology 49: 359-66. (2005).
38. Roses A and AM S. Perspective on a pathogenesis and treatment of Alzheimer's disease. Alzheimer's Dementia 2: 59-70. (2006).
39. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006).
40. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70: 177-88. (2005).
41. Pedersen WA and Flynn ER. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 17: 500-6. (2004).
42. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S and Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199: 265-73. (2006).
43. McEwen B Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann New York Acad Sci 933: 265-77. (2001).
44. Andrews R and Walker B. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 96: 513-23. (1999).
45. Qiu W and Folstein M. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 27: 190-8. (2006).
46. Watson G, Cholerton B, Reger M, Baker L, Plymate S, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatric Psych 13: 950-8. (2005).
47. Geldmacher D, Fritsch T. McClendon M, Lerner A and Landreth G. A pilot study of pioglitazone in Alzheimer Disease. Int Conf Alz Dis Rel Dementias; (2006).
48. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T. et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. Brit Med J 315: 1045-9. (1997).
49. Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J. et al. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology, 70: 146-52. (1999).
50. Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA. et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci 903: 222-8. (2000).